159 related articles for article (PubMed ID: 34771674)
1. Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1.
Sun C; Nagaoka K; Kobayashi Y; Nakagawa H; Kakimi K; Nakajima J
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771674
[TBL] [Abstract][Full Text] [Related]
2. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
[TBL] [Abstract][Full Text] [Related]
3. Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine.
Morisaki S; Onishi H; Morisaki T; Kubo M; Umebayashi M; Tanaka H; Koya N; Nakagawa S; Tsujimura K; Yoshimura S; Yew PY; Kiyotani K; Nakamura Y; Nakamura M; Kitazono T; Morisaki T
Front Immunol; 2023; 14():1223331. PubMed ID: 37881436
[TBL] [Abstract][Full Text] [Related]
4. Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors.
Bulgarelli J; Tazzari M; Granato AM; Ridolfi L; Maiocchi S; de Rosa F; Petrini M; Pancisi E; Gentili G; Vergani B; Piccinini F; Carbonaro A; Leone BE; Foschi G; Ancarani V; Framarini M; Guidoboni M
Front Immunol; 2019; 10():2353. PubMed ID: 31649669
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
6. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
[TBL] [Abstract][Full Text] [Related]
7. Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy.
Nagaoka K; Shirai M; Taniguchi K; Hosoi A; Sun C; Kobayashi Y; Maejima K; Fujita M; Nakagawa H; Nomura S; Kakimi K
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093158
[TBL] [Abstract][Full Text] [Related]
8. Identification of Neoantigens in Two Murine Gastric Cancer Cell Lines Leading to the Neoantigen-Based Immunotherapy.
Nagaoka K; Sun C; Kobayashi Y; Kanaseki T; Tokita S; Komatsu T; Maejima K; Futami J; Nomura S; Udaka K; Nakagawa H; Torigoe T; Kakimi K
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008270
[TBL] [Abstract][Full Text] [Related]
9. Functional antigen processing and presentation mechanism as a prerequisite factor of response to treatment with dendritic cell vaccines and anti-PD-1 in preclinical murine LLC1 and GL261 tumor models.
Žilionytė K; Bagdzevičiūtė U; Mlynska A; Urbštaitė E; Paberalė E; Dobrovolskienė N; Krasko JA; Pašukonienė V
Cancer Immunol Immunother; 2022 Nov; 71(11):2691-2700. PubMed ID: 35364740
[TBL] [Abstract][Full Text] [Related]
10. Adaptable antigen matrix platforms for peptide vaccination strategies and T cell-mediated anti-tumor immunity.
Schetters STT; Li RJE; Kruijssen LJW; Engels S; Ambrosini M; Garcia-Vallejo JJ; Kalay H; Unger WWJ; van Kooyk Y
Biomaterials; 2020 Dec; 262():120342. PubMed ID: 32905903
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
12. Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma.
Ichimiya S; Fujimura A; Masuda M; Masuda S; Yasumatsu R; Umebayashi M; Tanaka H; Koya N; Nakagawa S; Yew PY; Yoshimura S; Onishi H; Nakamura M; Nakamura Y; Morisaki T
Immunol Invest; 2022 Jul; 51(5):1498-1514. PubMed ID: 34486463
[TBL] [Abstract][Full Text] [Related]
13. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
[TBL] [Abstract][Full Text] [Related]
14. Cytosolic Delivery of Thiolated Neoantigen Nano-Vaccine Combined with Immune Checkpoint Blockade to Boost Anti-Cancer T Cell Immunity.
Zhang D; Lin Z; Wu M; Cai Z; Zheng Y; He L; Li Z; Zhou J; Sun L; Chen G; Zeng Y; Li J; Liu J; Yang H; Liu X
Adv Sci (Weinh); 2021 Mar; 8(6):2003504. PubMed ID: 33747739
[TBL] [Abstract][Full Text] [Related]
15. Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy.
Keshari S; Shavkunov AS; Miao Q; Saha A; Williams CD; Highsmith AM; Pineda JE; Alspach E; Hu KH; Pauken KE; Chen K; Gubin MM
bioRxiv; 2024 Jan; ():. PubMed ID: 38187708
[TBL] [Abstract][Full Text] [Related]
16. Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression.
Nguyen KB; Roerden M; Copeland CJ; Backlund CM; Klop-Packel NG; Remba T; Kim B; Singh NK; Birnbaum ME; Irvine DJ; Spranger S
Elife; 2023 Aug; 12():. PubMed ID: 37548358
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
18. A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control.
Tondini E; Arakelian T; Oosterhuis K; Camps M; van Duikeren S; Han W; Arens R; Zondag G; van Bergen J; Ossendorp F
Oncoimmunology; 2019; 8(11):1652539. PubMed ID: 31646082
[TBL] [Abstract][Full Text] [Related]
19. A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses.
Arbelaez CA; Estrada J; Gessner MA; Glaus C; Morales AB; Mohn D; Phee H; Lipford JR; Johnston JA
NPJ Vaccines; 2020 Nov; 5(1):106. PubMed ID: 33298945
[TBL] [Abstract][Full Text] [Related]
20. Photothermal therapy combined with neoantigen cancer vaccination for effective immunotherapy against large established tumors and distant metastasis.
Nam J; Son S; Park KS; Moon JJ
Adv Ther (Weinh); 2021 Aug; 4(8):. PubMed ID: 34485685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
